Hypofractionated Radiotherapy in Breast Cancer

Completed · Not applicable

Conditions studied: Cancer, Breast, Inflammation

In brief

As the number of breast cancer (BrCA) survivors has markedly increased, clinicians are now seeking to reduce treatment-related toxicities and inconveniences of treatment, namely the traditional 6 weeks of daily radiation treatment (XRT). Skin thickening, fibrosis, and edema are some of the most common acute and potentially long-term debilitating toxicities of BrCA XRT. The purpose of this study is to learn if three weeks of daily radiation treatment (RT) to the breast is safe in breast cancer patients who are usually prescribed 6 weeks of daily radiation after breast surgery (e.g. lumpectomy or mastectomy) as standard of care.

Key facts

Study ID

NCT03167359

Run by

Emory University

People needed

74

Starts

2010-12-01

Expected to finish

2019-05-14

Last updated by the study team

2021-05-07

Who can join

Age: any, up to 50. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Participants must have one or more of the following characteristics and be eligible for breast or chest wall with or without regional nodal radiotherapy:
• Prior Chemotherapy for Breast Cancer
• Greater than 25 cm of breast separation (the largest distance on an axial slice of the planning CT simulation scan between the entry and exit points of the radiation beam on the body)
• Non-Caucasian Race
• Less than or equal to 50 years of age
• Requiring regional nodal irradiation without evidence of N3 disease

You may not qualify if…

• Males will be excluded
• Women who are pregnant or nursing a child may not take part in this study

Where it is running

• Emory University — Atlanta, Georgia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.